nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—VDR—Ovarian Infertility Genes—DAZL—testicular cancer	0.0442	0.545	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.0167	0.206	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC2A6—testicular cancer	0.00658	0.0812	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—HPGDS—testicular cancer	0.00358	0.0442	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—HPGDS—testicular cancer	0.00262	0.0323	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—HPGDS—testicular cancer	0.0021	0.0258	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MMP2—testicular cancer	0.00105	0.013	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—DNMT3L—testicular cancer	0.00101	0.0124	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00101	0.0124	CbGpPWpGaD
Paricalcitol—Constipation—Etoposide—testicular cancer	0.000873	0.00095	CcSEcCtD
Paricalcitol—Pain—Etoposide—testicular cancer	0.000873	0.00095	CcSEcCtD
Paricalcitol—Urinary tract infection—Epirubicin—testicular cancer	0.000872	0.000949	CcSEcCtD
Paricalcitol—Conjunctivitis—Epirubicin—testicular cancer	0.000872	0.000949	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000865	0.000942	CcSEcCtD
Paricalcitol—Sweating—Epirubicin—testicular cancer	0.00086	0.000936	CcSEcCtD
Paricalcitol—Dizziness—Ifosfamide—testicular cancer	0.000855	0.00093	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—testicular cancer	0.000854	0.000929	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—testicular cancer	0.00085	0.000925	CcSEcCtD
Paricalcitol—Epistaxis—Epirubicin—testicular cancer	0.000846	0.000921	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—testicular cancer	0.000844	0.000918	CcSEcCtD
Paricalcitol—Weight decreased—Doxorubicin—testicular cancer	0.000842	0.000917	CcSEcCtD
Paricalcitol—Sinusitis—Epirubicin—testicular cancer	0.000842	0.000916	CcSEcCtD
Paricalcitol—Feeling abnormal—Etoposide—testicular cancer	0.000841	0.000915	CcSEcCtD
Paricalcitol—Nausea—Dactinomycin—testicular cancer	0.000838	0.000912	CcSEcCtD
Paricalcitol—Pneumonia—Doxorubicin—testicular cancer	0.000835	0.000909	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Etoposide—testicular cancer	0.000835	0.000908	CcSEcCtD
Paricalcitol—Infestation NOS—Doxorubicin—testicular cancer	0.00083	0.000903	CcSEcCtD
Paricalcitol—Infestation—Doxorubicin—testicular cancer	0.00083	0.000903	CcSEcCtD
Paricalcitol—Vomiting—Ifosfamide—testicular cancer	0.000822	0.000894	CcSEcCtD
Paricalcitol—Hypersensitivity—Cisplatin—testicular cancer	0.000821	0.000893	CcSEcCtD
Paricalcitol—Rash—Ifosfamide—testicular cancer	0.000815	0.000887	CcSEcCtD
Paricalcitol—Dermatitis—Ifosfamide—testicular cancer	0.000814	0.000886	CcSEcCtD
Paricalcitol—Urticaria—Etoposide—testicular cancer	0.000811	0.000882	CcSEcCtD
Paricalcitol—Abdominal pain—Etoposide—testicular cancer	0.000807	0.000878	CcSEcCtD
Paricalcitol—Body temperature increased—Etoposide—testicular cancer	0.000807	0.000878	CcSEcCtD
Paricalcitol—Urinary tract infection—Doxorubicin—testicular cancer	0.000807	0.000878	CcSEcCtD
Paricalcitol—Conjunctivitis—Doxorubicin—testicular cancer	0.000807	0.000878	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—testicular cancer	0.000804	0.000875	CcSEcCtD
Paricalcitol—Hypoaesthesia—Epirubicin—testicular cancer	0.000801	0.000872	CcSEcCtD
Paricalcitol—Asthenia—Cisplatin—testicular cancer	0.000799	0.00087	CcSEcCtD
Paricalcitol—Pharyngitis—Epirubicin—testicular cancer	0.000799	0.00087	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—testicular cancer	0.000799	0.000869	CcSEcCtD
Paricalcitol—Sweating—Doxorubicin—testicular cancer	0.000796	0.000866	CcSEcCtD
Paricalcitol—Urinary tract disorder—Epirubicin—testicular cancer	0.000795	0.000866	CcSEcCtD
Paricalcitol—Oedema peripheral—Epirubicin—testicular cancer	0.000793	0.000863	CcSEcCtD
Paricalcitol—Connective tissue disorder—Epirubicin—testicular cancer	0.000791	0.000861	CcSEcCtD
Paricalcitol—Urethral disorder—Epirubicin—testicular cancer	0.000789	0.000859	CcSEcCtD
Paricalcitol—Epistaxis—Doxorubicin—testicular cancer	0.000783	0.000852	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—testicular cancer	0.000781	0.00085	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—testicular cancer	0.000779	0.000847	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—testicular cancer	0.000777	0.000846	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—testicular cancer	0.000776	0.000844	CcSEcCtD
Paricalcitol—Chills—Methotrexate—testicular cancer	0.000772	0.00084	CcSEcCtD
Paricalcitol—Nausea—Ifosfamide—testicular cancer	0.000768	0.000835	CcSEcCtD
Paricalcitol—Diarrhoea—Cisplatin—testicular cancer	0.000762	0.00083	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—testicular cancer	0.00076	0.000828	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—testicular cancer	0.000754	0.00082	CcSEcCtD
Paricalcitol—Eye disorder—Epirubicin—testicular cancer	0.000753	0.000819	CcSEcCtD
Paricalcitol—Hypersensitivity—Etoposide—testicular cancer	0.000752	0.000818	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—testicular cancer	0.000749	0.000815	CcSEcCtD
Paricalcitol—Cardiac disorder—Epirubicin—testicular cancer	0.000747	0.000813	CcSEcCtD
Paricalcitol—Hypoaesthesia—Doxorubicin—testicular cancer	0.000741	0.000807	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—testicular cancer	0.00074	0.000805	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—testicular cancer	0.000736	0.000801	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—testicular cancer	0.000734	0.000799	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—testicular cancer	0.000734	0.000798	CcSEcCtD
Paricalcitol—Asthenia—Etoposide—testicular cancer	0.000732	0.000797	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—testicular cancer	0.000732	0.000797	CcSEcCtD
Paricalcitol—Angiopathy—Epirubicin—testicular cancer	0.000731	0.000795	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—testicular cancer	0.00073	0.000795	CcSEcCtD
Paricalcitol—Immune system disorder—Epirubicin—testicular cancer	0.000727	0.000792	CcSEcCtD
Paricalcitol—Mediastinal disorder—Epirubicin—testicular cancer	0.000726	0.00079	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—testicular cancer	0.000725	0.000789	CcSEcCtD
Paricalcitol—Chills—Epirubicin—testicular cancer	0.000723	0.000786	CcSEcCtD
Paricalcitol—Pruritus—Etoposide—testicular cancer	0.000722	0.000786	CcSEcCtD
Paricalcitol—Arrhythmia—Epirubicin—testicular cancer	0.000719	0.000783	CcSEcCtD
Paricalcitol—Alopecia—Epirubicin—testicular cancer	0.000712	0.000774	CcSEcCtD
Paricalcitol—Vomiting—Cisplatin—testicular cancer	0.000708	0.000771	CcSEcCtD
Paricalcitol—Mental disorder—Epirubicin—testicular cancer	0.000706	0.000768	CcSEcCtD
Paricalcitol—Rash—Cisplatin—testicular cancer	0.000702	0.000764	CcSEcCtD
Paricalcitol—Dermatitis—Cisplatin—testicular cancer	0.000702	0.000764	CcSEcCtD
Paricalcitol—Malnutrition—Epirubicin—testicular cancer	0.000701	0.000763	CcSEcCtD
Paricalcitol—Diarrhoea—Etoposide—testicular cancer	0.000698	0.00076	CcSEcCtD
Paricalcitol—Eye disorder—Doxorubicin—testicular cancer	0.000696	0.000758	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—testicular cancer	0.000695	0.000756	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—testicular cancer	0.000692	0.000754	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—testicular cancer	0.000692	0.000753	CcSEcCtD
Paricalcitol—Tension—Epirubicin—testicular cancer	0.000688	0.000749	CcSEcCtD
Paricalcitol—Dysgeusia—Epirubicin—testicular cancer	0.000687	0.000747	CcSEcCtD
Paricalcitol—Nervousness—Epirubicin—testicular cancer	0.000681	0.000741	CcSEcCtD
Paricalcitol—Back pain—Epirubicin—testicular cancer	0.000678	0.000738	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—testicular cancer	0.000676	0.000736	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—testicular cancer	0.000676	0.000735	CcSEcCtD
Paricalcitol—Dizziness—Etoposide—testicular cancer	0.000675	0.000735	CcSEcCtD
Paricalcitol—Muscle spasms—Epirubicin—testicular cancer	0.000674	0.000734	CcSEcCtD
Paricalcitol—Immune system disorder—Doxorubicin—testicular cancer	0.000673	0.000732	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—testicular cancer	0.000673	0.000732	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000672	0.000731	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—testicular cancer	0.000671	0.00073	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—testicular cancer	0.000669	0.000728	CcSEcCtD
Paricalcitol—Arrhythmia—Doxorubicin—testicular cancer	0.000666	0.000724	CcSEcCtD
Paricalcitol—Nausea—Cisplatin—testicular cancer	0.000662	0.00072	CcSEcCtD
Paricalcitol—Alopecia—Doxorubicin—testicular cancer	0.000658	0.000717	CcSEcCtD
Paricalcitol—Cough—Methotrexate—testicular cancer	0.000654	0.000711	CcSEcCtD
Paricalcitol—Mental disorder—Doxorubicin—testicular cancer	0.000653	0.00071	CcSEcCtD
Paricalcitol—Ill-defined disorder—Epirubicin—testicular cancer	0.00065	0.000708	CcSEcCtD
Paricalcitol—Vomiting—Etoposide—testicular cancer	0.000649	0.000706	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—testicular cancer	0.000649	0.000706	CcSEcCtD
Paricalcitol—Anaemia—Epirubicin—testicular cancer	0.000648	0.000705	CcSEcCtD
Paricalcitol—Agitation—Epirubicin—testicular cancer	0.000644	0.000701	CcSEcCtD
Paricalcitol—Rash—Etoposide—testicular cancer	0.000644	0.0007	CcSEcCtD
Paricalcitol—Dermatitis—Etoposide—testicular cancer	0.000643	0.0007	CcSEcCtD
Paricalcitol—Headache—Etoposide—testicular cancer	0.000639	0.000696	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—testicular cancer	0.000638	0.000694	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—testicular cancer	0.000638	0.000694	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—testicular cancer	0.000638	0.000694	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—testicular cancer	0.000637	0.000693	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—testicular cancer	0.000635	0.000691	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000633	0.000689	CcSEcCtD
Paricalcitol—Malaise—Epirubicin—testicular cancer	0.000632	0.000688	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—testicular cancer	0.00063	0.000686	CcSEcCtD
Paricalcitol—Nervousness—Doxorubicin—testicular cancer	0.00063	0.000686	CcSEcCtD
Paricalcitol—Vertigo—Epirubicin—testicular cancer	0.00063	0.000685	CcSEcCtD
Paricalcitol—Syncope—Epirubicin—testicular cancer	0.000629	0.000684	CcSEcCtD
Paricalcitol—Leukopenia—Epirubicin—testicular cancer	0.000628	0.000683	CcSEcCtD
Paricalcitol—Back pain—Doxorubicin—testicular cancer	0.000627	0.000683	CcSEcCtD
Paricalcitol—Muscle spasms—Doxorubicin—testicular cancer	0.000624	0.000679	CcSEcCtD
Paricalcitol—Palpitations—Epirubicin—testicular cancer	0.00062	0.000674	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—testicular cancer	0.000616	0.000671	CcSEcCtD
Paricalcitol—Loss of consciousness—Epirubicin—testicular cancer	0.000616	0.000671	CcSEcCtD
Paricalcitol—Cough—Epirubicin—testicular cancer	0.000612	0.000666	CcSEcCtD
Paricalcitol—Infection—Methotrexate—testicular cancer	0.000607	0.000661	CcSEcCtD
Paricalcitol—Nausea—Etoposide—testicular cancer	0.000606	0.00066	CcSEcCtD
Paricalcitol—Hypertension—Epirubicin—testicular cancer	0.000605	0.000659	CcSEcCtD
Paricalcitol—Ill-defined disorder—Doxorubicin—testicular cancer	0.000602	0.000655	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—testicular cancer	0.0006	0.000652	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—testicular cancer	0.0006	0.000652	CcSEcCtD
Paricalcitol—Myalgia—Epirubicin—testicular cancer	0.000597	0.00065	CcSEcCtD
Paricalcitol—Chest pain—Epirubicin—testicular cancer	0.000597	0.00065	CcSEcCtD
Paricalcitol—Arthralgia—Epirubicin—testicular cancer	0.000597	0.00065	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—testicular cancer	0.000596	0.000649	CcSEcCtD
Paricalcitol—Anxiety—Epirubicin—testicular cancer	0.000595	0.000647	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—testicular cancer	0.000594	0.000646	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000593	0.000645	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—testicular cancer	0.000591	0.000643	CcSEcCtD
Paricalcitol—Discomfort—Epirubicin—testicular cancer	0.00059	0.000642	CcSEcCtD
Paricalcitol—Malaise—Doxorubicin—testicular cancer	0.000585	0.000637	CcSEcCtD
Paricalcitol—Dry mouth—Epirubicin—testicular cancer	0.000584	0.000635	CcSEcCtD
Paricalcitol—Vertigo—Doxorubicin—testicular cancer	0.000583	0.000634	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—testicular cancer	0.000583	0.000634	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—testicular cancer	0.000582	0.000633	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—testicular cancer	0.000581	0.000632	CcSEcCtD
Paricalcitol—Confusional state—Epirubicin—testicular cancer	0.000577	0.000628	CcSEcCtD
Paricalcitol—Palpitations—Doxorubicin—testicular cancer	0.000573	0.000624	CcSEcCtD
Paricalcitol—Oedema—Epirubicin—testicular cancer	0.000572	0.000623	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—testicular cancer	0.000571	0.000622	CcSEcCtD
Paricalcitol—Loss of consciousness—Doxorubicin—testicular cancer	0.00057	0.00062	CcSEcCtD
Paricalcitol—Infection—Epirubicin—testicular cancer	0.000568	0.000619	CcSEcCtD
Paricalcitol—Cough—Doxorubicin—testicular cancer	0.000566	0.000616	CcSEcCtD
Paricalcitol—Shock—Epirubicin—testicular cancer	0.000563	0.000613	CcSEcCtD
Paricalcitol—Nervous system disorder—Epirubicin—testicular cancer	0.000561	0.000611	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—testicular cancer	0.00056	0.000609	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000557	0.000606	CcSEcCtD
Paricalcitol—Skin disorder—Epirubicin—testicular cancer	0.000556	0.000605	CcSEcCtD
Paricalcitol—Hyperhidrosis—Epirubicin—testicular cancer	0.000553	0.000602	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—testicular cancer	0.000553	0.000602	CcSEcCtD
Paricalcitol—Arthralgia—Doxorubicin—testicular cancer	0.000552	0.000601	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—testicular cancer	0.000552	0.000601	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—testicular cancer	0.000552	0.000601	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—testicular cancer	0.00055	0.000599	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—testicular cancer	0.000549	0.000597	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000548	0.000597	CcSEcCtD
Paricalcitol—Discomfort—Doxorubicin—testicular cancer	0.000546	0.000594	CcSEcCtD
Paricalcitol—Anorexia—Epirubicin—testicular cancer	0.000545	0.000594	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—testicular cancer	0.000545	0.000593	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—testicular cancer	0.000544	0.000592	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—testicular cancer	0.00054	0.000588	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—testicular cancer	0.000538	0.000586	CcSEcCtD
Paricalcitol—Hypotension—Epirubicin—testicular cancer	0.000535	0.000582	CcSEcCtD
Paricalcitol—Confusional state—Doxorubicin—testicular cancer	0.000534	0.000581	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—testicular cancer	0.000531	0.000578	CcSEcCtD
Paricalcitol—Oedema—Doxorubicin—testicular cancer	0.000529	0.000576	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000528	0.000574	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—testicular cancer	0.000527	0.000574	CcSEcCtD
Paricalcitol—Infection—Doxorubicin—testicular cancer	0.000526	0.000572	CcSEcCtD
Paricalcitol—Pain—Methotrexate—testicular cancer	0.000523	0.000569	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000521	0.000567	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—testicular cancer	0.000521	0.000567	CcSEcCtD
Paricalcitol—Nervous system disorder—Doxorubicin—testicular cancer	0.000519	0.000565	CcSEcCtD
Paricalcitol—Insomnia—Epirubicin—testicular cancer	0.000517	0.000563	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—testicular cancer	0.000514	0.00056	CcSEcCtD
Paricalcitol—Paraesthesia—Epirubicin—testicular cancer	0.000514	0.000559	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000512	0.000557	CcSEcCtD
Paricalcitol—Dyspnoea—Epirubicin—testicular cancer	0.00051	0.000555	CcSEcCtD
Paricalcitol—Somnolence—Epirubicin—testicular cancer	0.000509	0.000554	CcSEcCtD
Paricalcitol—Anorexia—Doxorubicin—testicular cancer	0.000505	0.000549	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—testicular cancer	0.000504	0.000548	CcSEcCtD
Paricalcitol—Dyspepsia—Epirubicin—testicular cancer	0.000504	0.000548	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—testicular cancer	0.0005	0.000544	CcSEcCtD
Paricalcitol—Decreased appetite—Epirubicin—testicular cancer	0.000497	0.000541	CcSEcCtD
Paricalcitol—Hypotension—Doxorubicin—testicular cancer	0.000495	0.000538	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000494	0.000538	CcSEcCtD
Paricalcitol—Fatigue—Epirubicin—testicular cancer	0.000493	0.000537	CcSEcCtD
Paricalcitol—Constipation—Epirubicin—testicular cancer	0.000489	0.000532	CcSEcCtD
Paricalcitol—Pain—Epirubicin—testicular cancer	0.000489	0.000532	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—testicular cancer	0.000486	0.000529	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—testicular cancer	0.000483	0.000526	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—testicular cancer	0.000483	0.000526	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000482	0.000525	CcSEcCtD
Paricalcitol—Insomnia—Doxorubicin—testicular cancer	0.000479	0.000521	CcSEcCtD
Paricalcitol—Paraesthesia—Doxorubicin—testicular cancer	0.000475	0.000517	CcSEcCtD
Paricalcitol—Dyspnoea—Doxorubicin—testicular cancer	0.000472	0.000514	CcSEcCtD
Paricalcitol—Feeling abnormal—Epirubicin—testicular cancer	0.000471	0.000513	CcSEcCtD
Paricalcitol—Somnolence—Doxorubicin—testicular cancer	0.000471	0.000512	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Epirubicin—testicular cancer	0.000468	0.000509	CcSEcCtD
Paricalcitol—Dyspepsia—Doxorubicin—testicular cancer	0.000466	0.000507	CcSEcCtD
Paricalcitol—Decreased appetite—Doxorubicin—testicular cancer	0.00046	0.000501	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000457	0.000497	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—testicular cancer	0.000456	0.000497	CcSEcCtD
Paricalcitol—Urticaria—Epirubicin—testicular cancer	0.000455	0.000495	CcSEcCtD
Paricalcitol—Pain—Doxorubicin—testicular cancer	0.000453	0.000493	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—testicular cancer	0.000453	0.000493	CcSEcCtD
Paricalcitol—Abdominal pain—Epirubicin—testicular cancer	0.000452	0.000492	CcSEcCtD
Paricalcitol—Body temperature increased—Epirubicin—testicular cancer	0.000452	0.000492	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—testicular cancer	0.00045	0.00049	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—HPGDS—testicular cancer	0.000448	0.00553	CbGpPWpGaD
Paricalcitol—Asthenia—Methotrexate—testicular cancer	0.000439	0.000477	CcSEcCtD
Paricalcitol—Feeling abnormal—Doxorubicin—testicular cancer	0.000436	0.000475	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000433	0.000471	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—testicular cancer	0.000433	0.000471	CcSEcCtD
Paricalcitol—Hypersensitivity—Epirubicin—testicular cancer	0.000422	0.000459	CcSEcCtD
Paricalcitol—Urticaria—Doxorubicin—testicular cancer	0.000421	0.000458	CcSEcCtD
Paricalcitol—Abdominal pain—Doxorubicin—testicular cancer	0.000418	0.000455	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—testicular cancer	0.000418	0.000455	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—testicular cancer	0.000418	0.000455	CcSEcCtD
Paricalcitol—Asthenia—Epirubicin—testicular cancer	0.000411	0.000447	CcSEcCtD
Paricalcitol—Pruritus—Epirubicin—testicular cancer	0.000405	0.000441	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—testicular cancer	0.000404	0.00044	CcSEcCtD
Paricalcitol—Diarrhoea—Epirubicin—testicular cancer	0.000391	0.000426	CcSEcCtD
Paricalcitol—Hypersensitivity—Doxorubicin—testicular cancer	0.00039	0.000424	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—testicular cancer	0.000389	0.000423	CcSEcCtD
Paricalcitol—Rash—Methotrexate—testicular cancer	0.000385	0.00042	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—testicular cancer	0.000385	0.000419	CcSEcCtD
Paricalcitol—Headache—Methotrexate—testicular cancer	0.000383	0.000417	CcSEcCtD
Paricalcitol—Asthenia—Doxorubicin—testicular cancer	0.00038	0.000413	CcSEcCtD
Paricalcitol—Dizziness—Epirubicin—testicular cancer	0.000378	0.000412	CcSEcCtD
Paricalcitol—Pruritus—Doxorubicin—testicular cancer	0.000375	0.000408	CcSEcCtD
Paricalcitol—Vomiting—Epirubicin—testicular cancer	0.000364	0.000396	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—testicular cancer	0.000363	0.000395	CcSEcCtD
Paricalcitol—Diarrhoea—Doxorubicin—testicular cancer	0.000362	0.000394	CcSEcCtD
Paricalcitol—Rash—Epirubicin—testicular cancer	0.000361	0.000393	CcSEcCtD
Paricalcitol—Dermatitis—Epirubicin—testicular cancer	0.00036	0.000392	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—HPGDS—testicular cancer	0.000358	0.00442	CbGpPWpGaD
Paricalcitol—Headache—Epirubicin—testicular cancer	0.000358	0.00039	CcSEcCtD
Paricalcitol—VDR—Gene Expression—H2AFZ—testicular cancer	0.000353	0.00435	CbGpPWpGaD
Paricalcitol—Dizziness—Doxorubicin—testicular cancer	0.00035	0.000381	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.00034	0.00419	CbGpPWpGaD
Paricalcitol—Nausea—Epirubicin—testicular cancer	0.00034	0.00037	CcSEcCtD
Paricalcitol—Vomiting—Doxorubicin—testicular cancer	0.000337	0.000366	CcSEcCtD
Paricalcitol—Rash—Doxorubicin—testicular cancer	0.000334	0.000363	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—testicular cancer	0.000333	0.000363	CcSEcCtD
Paricalcitol—Headache—Doxorubicin—testicular cancer	0.000332	0.000361	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—STK11—testicular cancer	0.000326	0.00402	CbGpPWpGaD
Paricalcitol—Nausea—Doxorubicin—testicular cancer	0.000314	0.000342	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—STK11—testicular cancer	0.00026	0.00321	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HPGDS—testicular cancer	5.82e-05	0.000717	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—STK11—testicular cancer	4.23e-05	0.000521	CbGpPWpGaD
